U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07077005) titled 'Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy' on July 10.
Brief Summary: Patients with hypertrophic obstructive cardiomyopathy and New York Heart Association Class I-II under stable treatment with mavacamten (at least 12 weeks without change of dosage) and a peak left ventricular outflow tract obstruction <50mmHg undergo either 6 weeks of structured moderate intensity endurance and resistance training (supervised, 3x/week, intervention, IT) or usual care (UC). Patients within 1 hour of travel to the training venue will be referred to IT, while those with more than 1 hour will join UC.
At baseline (visit 1,...